Last reviewed · How we verify
ALKAVERVIR
Alkavervir is a marketed drug that interacts with a specific molecular target to address its primary indication. The key composition patent for Alkavervir is set to expire in 2028, which currently provides a strong barrier to generic competition. The primary risk facing Alkavervir is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | ALKAVERVIR |
|---|---|
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |